


In the Claims

1. (Original) An 1-[(indol-3-yl)carbonyl]piperazine derivative having the general formula I



Formula I

wherein

R represents 1-4 substituents independently selected from H, (C₁₋₄)alkyl (optionally substituted with halogen), (C₁₋₄)alkyloxy (optionally substituted with halogen), halogen, OH, NH₂, CN and NO₂;

R₁ is (C₅₋₈)cycloalkyl or (C₅₋₈)cycloalkenyl;

R₂ is H, methyl or ethyl;

R₃, R_{3'}, R_{4'}, R_{4'}, R₅, R_{5'} and R_{6'} are independently hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, halogen or OH;

R₆ is hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, halogen or OH; or

R₆ forms together with R₇ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R₇ forms together with R₆ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O

and S; or

R₇ is H, (C₁₋₄)alkyl or (C₃₋₅)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C₁₋₄)alkyloxy; or a pharmaceutically acceptable salt thereof.

2. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R₂ is H and R₁ is (C₅₋₆)cycloalkyl.

3. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R is (C₁₋₄)alkyloxy or halogen.

4 (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R represents a methoxy group at the 7-position of the indole ring.

5. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 4, wherein R₃, R_{3'}, R_{4'}, R₅, R_{5'} and R_{6'} are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.

6. (Currently Amended)) The 1-[(indol-3-yl)carbonyl]piperazine derivative according to ~~formula I of claim 1, which is selected from~~ wherein the derivative is selected from the group consisting of

1-[[1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl]carbonyl]-3,5-dimethyl-4-ethylpiperazine;

1-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-yl]carbonyl}-
3,4,5-trimethylpiperazine;

(*S*)-1-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-
yl]carbonyl}-3,4-dimethylpiperazine;

(*S*)-2-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-
yl]carbonyl}-octahydro-2*H*-pyrido-[1, 2-*a*]pyrazine;

(*S*)-2-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-
yl]carbonyl}-octahydro-2*H*-pyrrolo-[1, 2-*a*]pyrazine; and

(*S*)-2-{[1-(cyclopentylmethyl)-7-methoxy-1*H*-indol-3-
yl]carbonyl}-octahydro-2*H*-pyrido-[1, 2-*a*]pyrazine;

or a pharmaceutically acceptable salt thereof of each individual
derivative.

7. (Canceled).

8. (Currently Amended) A pharmaceutical composition, comprising:

~~an~~ the 1-[(indol-3-yl)carbonyl]piperazine derivative of any
~~one of claims 1-6 together with claim 1, and~~

a pharmaceutically acceptable carrier ~~therefor~~.

9. (Canceled).

10. (New) A method of inducing a agonist effect of a CB-1
receptor in a patient in need thereof, comprising:

administering an effective amount of the derivative
according to claim 1 to induce an agonistic effect at the CB-1
receptor.

11. (New) A method of treating pain in a patient in need thereof,
comprising:

administering an effective amount of the derivative
according to claim 1.